Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was formerly known as Isis Resources plc and changed its name to Verona Pharma plc in September 2006. The company was incorporated in 2005 and is based in London, the United Kingdom. As of October 7, 2025, Verona Pharma plc operates as a subsidiary of Merck Sharp & Dohme LLC.
Frequently asked questions
What sector does Verona Pharma PLC ADR (VRNA) operate in?
Verona Pharma PLC ADR belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Verona Pharma PLC ADR (VRNA) current stock price?
As of the latest data, Verona Pharma PLC ADR stock price is $106.91, with a previous close of $106.91.
What is Verona Pharma PLC ADR (VRNA) current market capitalization?
Verona Pharma PLC ADR market cap is approximately 9.09 billion.
What is Verona Pharma PLC ADR (VRNA) Earnings Per Share (EPS)?
The trailing EPS is -$1.04, and the forward EPS is $2.49.
Does Verona Pharma PLC ADR (VRNA) pay dividends?
No. Verona Pharma PLC ADR does not pay a dividend.
What is Verona Pharma PLC ADR (VRNA) beta (volatility) score?
Verona Pharma PLC ADR has a beta of 0.052, indicating lower volatility than the overall market.